Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved ziftomenib for adult patients with relapsed or refractory acute myeloid leukemia with a ...

ORLANDO, Fla. — Adding epcoritamab (Epkinly) to the standard-of-care (SOC) therapy of lenalidomide (Revlimid) and rituximab (Rituxan), a combination known as R 2, lowered the risk for disease ...

Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said. Treatment with CAR-T cell therapy Breyanzi ...

Please provide your email address to receive an email when new articles are posted on . Teclistamab plus daratumumab hyaluronidase-fihj received approval for adults with relapsed or refractory ...

Sofi-cel, an allogeneic CAR-T therapy, targets CD7 and uses CRISPR/Cas9 to prevent fratricide and reduce graft-versus-host disease risk. The FDA's breakthrough therapy designation facilitates ...

Monjuvi in combination with lenalidomide and rituximab significantly improved PFS in patients with relapsed/refractory follicular lymphoma. The Food and Drug Administration (FDA) has approved Monjuvi ...

Real world outcomes of venetoclax combined with hypomethylating agents in acute myeloid leukemia and myelodysplastic syndrome: Insights from a tertiary care centre in Pakistan. This is an ASCO Meeting ...

– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...